SCHEDULE 3

“PART 3 Monitoring for indicative dose and analytical performance characteristics

5 Monitoring for compliance with the indicative dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

7 Screening for certain radionuclides, or screening for an individual radionuclide
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9 Screening strategies for gross alpha activity and gross beta activity
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12 Calculation of the indicative dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

14 Performance characteristics and methods of analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”

Regulations revoked (20.11.2017) by The Private Water Supplies (Wales) Regulations 2017 (S.I. 2017/1041), reg. 24(1)(d) (with reg. 3)
Regulation 8